Preclinical research in mice has explored modulating the chemerin/CMKLR1 axis, using chemerin-derived peptides or CMKLR1 inhibitors, for potential treatments for neuropathic pain and allergic airway inflammation. Here, RARRES2 is linked to neuropathic pain.